BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Oxygen Biotherapeutics, Inc. 

(Formerly Synthetic Blood International, Inc.)
3189 Airway Avenue, Building C
Costa Mesa  California  92626  U.S.A.
Phone: 800-809-6054 Fax: 714-427-6361


SEARCH JOBS








 Company News
Oxygen Biotherapeutics, Inc. (OXBT) Announces The Appointment Of Industry Veteran Gerald Proehl To Its Board Of Directors 4/7/2014 7:30:01 AM    More...
Oxygen Biotherapeutics, Inc. (OXBT) Announces The Appointment Of Industry Veteran Gerald Proehl To Its Board Of Directors 4/4/2014 7:10:41 AM    More...
FDA Lifts Clinical Hold On Oxygen Biotherapeutics, Inc. (OXBT)'s Program 3/31/2014 7:53:03 AM    More...
Oxygen Biotherapeutics, Inc. (OXBT) Announces Proposed Public Offering 3/18/2014 9:11:15 AM    More...
Oxygen Biotherapeutics, Inc. (OXBT) Prices $52 Million Underwritten Offering 3/18/2014 7:01:18 AM    More...
Oxygen Biotherapeutics, Inc. (OXBT) Rockets As FDA Lifts Hold On Brain Injury Drug Oxycyte 3/4/2014 7:55:48 AM    More...
Oxygen Biotherapeutics, Inc. (OXBO) Release: Newly Published Cardiac Surgery Study Provides Further Evidence That Levosimendan Significantly Improves Post-Operative Kidney Function 2/13/2014 10:45:01 AM    More...
Oxygen Biotherapeutics, Inc. (OXBO) To Present At Two Upcoming Healthcare Investor Conferences 1/7/2014 7:24:54 AM    More...
Oxygen Biotherapeutics, Inc. (OXBO) Announces Key Details Of Phase 3 Trial Protocol For Levosimendan 1/6/2014 9:47:46 AM    More...
Oxygen Biotherapeutics, Inc. (OXBO) Provides A Business Review And Update In Conjunction With Filing Of Second Quarter Fiscal Year 2014 Financials 12/19/2013 8:43:04 AM    More...
12345678910...

//-->